Immunoglobulin Intravenous

Intravenous Immunoglobulin, IVIG

Mechanism :

Immune Globulin (Human) is a solvent/detergent treated sterile solution of immune globulin for parenteral administration; it contains no preservative. It is prepared by cold ethanol fractionation from human plasma.

Indication :

• Agammaglobulinemia
• Hypogammaglobulinemia
• Idiopathic thrombocytopenic purpura
• Kawasaki disease
• Dermatomyositis
• Guillain Barre syndrome
• Immunodeficiency-humoral primary and secondary

Contraindications :

Contraindicated in persons with isolated immunoglobulin A (IgA) deficiency. Such persons have the potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA. Should not be administered to patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.

Dosing :

ITP/Kawasaki syndrome:

IV infusion 2 gm/kg as single dose over 12 hours as soon as possible after onset of disease. 2nd dose if fever persists for 48 hours after 1st dose.

Immunodeficiency syndromes:

IV infusion 400 mg/kg once in 3 weeks. Dose depends on severity of infection.

Guillian Barre syndrome:

IV infusion 400 mg/kg once daily for 3-5 days depending on severity.

Adverse Effect :

Pyrexia, chills, nausea, vomiting, flushing of face, headache, fatigue, malaise, sweating, back pain, anaphylaxis, hypotension, dyspnea and tightness of chest.

Interaction :

Live vaccines (especially MMR): Active immunization with should be postponed until 3 months after the last administration of immunoglobulin.
If possi­ble an interval of 3 weeks should be observed after administration of live virus vaccines prior to immunoglobu­lin administration.

Hepatic Dose :